Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

GISP Supplement and Profiles, 2012

STD Surveillance, 2012

Requires Adobe Reader.

Figure A Data - Age of GISP Participants, 2012

Figure B Data - Race/Ethnicity of GISP Participants, 2012

Figure C Data - Percentage of GISP Participants Identifying as Men Who Have Sex with Men, 2000-2012

Figure D Data - Primary Antibiotic Used to Treat Gonorrhea among GISP Participants, 2012

Figure E Data - Secondary Antibiotic Used to Treat Gonorrhea among GISP Participants, 2012

Figure F Data - Resistance to Penicillin, Tetracycline, and Ciprofloxacin among GISP Isolates, 2012

Figure G Data – Distribution of Minimum Inhibitory Concentrations (MICs) of Ceftriaxone among GISP Isolates, 2008-2012

Figure H Data - Distribution of Minimum Inhibitory Concentrations (MICs) of Cefixime among GISP Isolates, 2009-2012

Figure I Data - Intermediate Resistance and Resistance to Ciprofloxacin among GISP Isolates, 2000-2012

Figure J Data - Distribution of Minimum Inhibitory Concentrations (MICs) to Azithromycin among GISP isolates, 2008-2012
 

The Gonococcal Isolate Surveillance Project (GISP), a national sentinel surveillance system, was established in 1986 to monitor trends in antimicrobial susceptibilities of Neisseria gonorrhoeae strains in the United States among selected sexually transmitted diseases (STD) clinics in approximately 25-30 GISP sentinel sites.

Annual reports were published for the years 1998–2007. Starting in 2008, site-specific GISP profiles have been published online each year.

The site-specific profiles on the right consist of figures depicting the demographic and clinical data of the men with gonorrhea enrolled in GISP and the antimicrobial susceptibility results of the Neisseria gonorrhoeae isolates submitted.

2012 GISP Supplement, Introduction, Figures and Tables

Figure 1. Distribution of Cefixime MICs, 2009-2012

Table 1. Distribution of Cefixime MICs, 2009–2012

Figure 2. Distribution of Ceftriaxone MICs, 2008-2012

Table 2. Distribution of Ceftriaxone MICs, 2008–2012

Figure 3. Distribution of Azithromycin MICs, 2008-2012

Table 3. Distribution of Azithromycin MICs, 2008–2012

Figure 4. Percentage of Neisseria gonorrhoeae Isolates that are Ciprofloxacin- Resistant by Sex of Sex Partner, 1995-2012

Top